Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group

Blood

Volumn 108, Issue 2, 2006, Pages 441-451

  Hilden, Joanne M ^a   Dinndorf, Patricia A ^b   Meerbaum, Sharon O ^b   Sather, Harland ^b   Villaluna, Doojduen ^b   Heerema, Nyla A ^b   McGlennen, Ron ^b   Smith, Franklin O ^b   Woods, William G ^b   Salzer, Wanda L ^b   Johnstone, Helen S ^b   Dreyer, Zoann ^b   Reaman, Gregory H ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE ISONICOTINATE; ETOPOSIDE; FOLINATE CALCIUM; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW TRANSPLANTATION; CHROMOSOME 11; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL DISEASE; GENE REARRANGEMENT; HEART DISEASE; HUMAN; HUMAN CELL; INFANT; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEWBORN; ONCOLOGY; PANCREAS DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DEFECT; SOUTHERN BLOTTING; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME;

EID: 33745961112     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-3011     Document Type: Article

References (33)

1. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999;17:445-455.
2. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for acute lymphoblastic leukemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol. 1994;86:284-290.
3. Chessels JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol. 2002;117:306-314.
4. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol. 1997;19:35-42.
5. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-1217.
6. Silverman SB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber cancer institute consortium. Cancer. 1997;80:2285-2295.
7. Reaman GH, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Group. J Clin Oncol. 1985;3:1513-1521.
8. Pui C-H, Evans WE. Editorial: acute lymphoblastic leukemia in infants [editorial]. J Clin Oncol. 1999;17:438-440.
9. Dinndorf PA, Reaman GR. Acute lymphoblastic leukemia in infants: evidence for B cell origin of disease by use of monoclonal antibody phenotyping. Blood. 1986;68:975-978.
10. Basso G, Putti C, Cantu-Rajnoldi A, et al. The immunophenotype in infant acute lymphoblastic leukemia: correlation with clinical outcome: an Italian multicentre study (AIEOP). Br J Haematol. 1992;81:184-191.
11. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia. 1995;9:762-769.
12. Heerema NA, Arthur DC, Sather H, et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children's Cancer Group. Blood. 1994;83:2274-2284.
13. Pui C-H, Ribeiro RC, Campana D, et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia. 1996;10:952-956.
14. Raimondi SC, Peiper SC, Kitchingman GR, Behm FG, Williams DL. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood. 1989;73:1627-1634.
15. Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reversetranscriptase polymerase chain reaction for t(4; 11)(q21;q23). Blood. 1995;86:3876-3882.
16. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1994;84:570-573.
17. Cimino G, Rapanotti MC, Ribolta A, et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemia. Leukemia. 1995;9:391-395.
18. Taki T, Ida K, Bessho F, et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia. 1996;10:1303-1307.
19. Heerema NA, Sather HN, Ge J, et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11): a report of the Children's Cancer Group. Leukemia. 1999;13:679-686.
20. Rubnitz JE, Camitta BM, Mahmoud H, et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3). J Clin Oncol. 1999;17:191-196.
21. Dreyer ZE, Steuber CP, Bowman WP, et al. High risk infant ALL- Improved survival with intensive chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1998;17:529a.
22. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood. 1993;81:2386-2393.
23. Repp R, Borkhardt A, Haupt E, et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia. 1995;9:210-215.
24. Hilden JM, Chen CS, Moore R, Frestedt J, Kersey JH. Heterogeneity in MLL/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia. Cancer Res. 1993;53:3853-3856.
25. Mitelman F, ed. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
28. Bernstein L, Anderson J, Pike M. Estimation of the proportional hazard in two-treatment group clinical trials. Biometrics. 1981;37:513-519.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
30. Breslow N. Analysis of survival data under the proportional hazards model. Int Stat Rev. 1975;43:45-58.
31. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:187-220.
32. Reaman GH, Steinherz PG, Gaynon PS, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep. 1987;71:1033-1038.
33. Beauchamp T, Lukens J, Sallan S, Pentz R, Ellenberg S, Weiner S. Phase II Window Studies in Pediatric Oncology Meeting Report. http://ctep.cancer.gov/ resources/phase2.html. Accessed August 2005.